MEK inhibitors 

(e.g., trametinib, cobimetinib, binimetinb )

Cardio-oncological evaluation*

before cancer treatment begins

Cardio-oncological evaluation*

every 3 months for 1 year, then every 6 months during cancer treatment

* A cardio-oncological evaluation will systematically include at least one visit with blood pressure, blood glucose, lipid profile, GFR calculation, ECG and trans-thoracic echocardiography (TTE). Measurements of global longitudinal strain and 3D LVEF (if feasible) are recommended with the same machine.